Bio-Techne Corporation announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent.

Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various senior global clinical and research positions at Novartis Oncology, a division of Novartis AG, including SVP & Global Head, Oncology Clinical Development. Dr. Klimovsky also served as Regional Medical Director, Latin America for Merck & Co.

and held several research and development roles of increasing responsibility at Bristol-Myers Squibb Company. Dr. Klimovsky received her M.D. from the Universidad de Buenos Aires. Dr. Klimovsky previously (from 2018 to Feb.

2024) served as a Director of Bellicum Pharmaceuticals, a company discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors.